AnaptysBio’s drug candidates rosnilimab and ANB032 hold key trial results ahead. Find out why ANAB stock is impacted by ...
Concerto Biosciences has dosed the first subject in a Phase I trial of the three-stain live biotherapeutic product, ENS-002, ...
Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...
The company has shown significant progress with its lead asset, soquelitinib, particularly in treating atopic dermatitis (AtD). The upcoming interim Phase 1 data, expected in December, has generated ...
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care ...
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing CohortInterim Data from Atopic Dermatitis Trial ...
SciBase is excited to announce a new collaboration aimed at revolutionizing early detection of atopic diseases in infants through the use of Electrical Impedance Spectroscopy (EIS) technology. This ...
The new Contact Allergen Management Program (CAMP) 2.0, from the American Contact Dermatitis Society (ACDS), is a web- and ...
The research aims to develop standardized diagnosis and treatment protocols for atopic dermatitis ... on improving disease understanding and management through medical education.
According to Dr Chu, the most holistic approach to improving quality of life for those grappling with atopic dermatitis is a combination of medical treatment, stress management, a consistent skincare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback